190 related articles for article (PubMed ID: 35081108)
1. Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9.
Goldwaser E; Laurent C; Lagarde N; Fabrega S; Nay L; Villoutreix BO; Jelsch C; Nicot AB; Loriot MA; Miteva MA
PLoS Comput Biol; 2022 Jan; 18(1):e1009820. PubMed ID: 35081108
[TBL] [Abstract][Full Text] [Related]
2. Large-scale evaluation of cytochrome P450 2C9 mediated drug interaction potential with machine learning-based consensus modeling.
Rácz A; Keserű GM
J Comput Aided Mol Des; 2020 Aug; 34(8):831-839. PubMed ID: 32221780
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C9-natural antiarthritic interactions: Evaluation of inhibition magnitude and prediction from in vitro data.
Tan BH; Ahemad N; Pan Y; Palanisamy UD; Othman I; Yiap BC; Ong CE
Biopharm Drug Dispos; 2018 Apr; 39(4):205-217. PubMed ID: 29488228
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes.
Wang Z; Sun W; Huang CK; Wang L; Xia MM; Cui X; Hu GX; Wang ZS
Drug Dev Ind Pharm; 2015 Apr; 41(4):613-6. PubMed ID: 24517573
[TBL] [Abstract][Full Text] [Related]
5. Screening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax Ginseng.
Xiao J; Chen D; Lin XX; Peng SF; Xiao MF; Huang WH; Wang YC; Peng JB; Zhang W; Ouyang DS; Chen Y
PLoS One; 2016; 11(2):e0147183. PubMed ID: 26845774
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
[TBL] [Abstract][Full Text] [Related]
7. CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes.
Plonka W; Stork C; Šícho M; Kirchmair J
Bioorg Med Chem; 2021 Sep; 46():116388. PubMed ID: 34488021
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
Huth F; Gardin A; Umehara K; He H
Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
[TBL] [Abstract][Full Text] [Related]
9. Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity.
Lim SYM; Binti Azidin AR; Ung YT; Al-Shagga M; Alshawsh MA; Mohamed Z; Ong CE; Pan Y
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):423-431. PubMed ID: 30306496
[TBL] [Abstract][Full Text] [Related]
10. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
13.
Zhang N; Liu J; Chen Z; Dou W
Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
[No Abstract] [Full Text] [Related]
14. Evaluation of machine learning models for cytochrome P450 3A4, 2D6, and 2C9 inhibition.
Gong C; Feng Y; Zhu J; Liu G; Tang Y; Li W
J Appl Toxicol; 2024 Mar; ():. PubMed ID: 38544296
[TBL] [Abstract][Full Text] [Related]
15. Differing Membrane Interactions of Two Highly Similar Drug-Metabolizing Cytochrome P450 Isoforms: CYP 2C9 and CYP 2C19.
Mustafa G; Nandekar PP; Bruce NJ; Wade RC
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487853
[TBL] [Abstract][Full Text] [Related]
16. In silico prediction of multiple-category classification model for cytochrome P450 inhibitors and non-inhibitors using machine-learning method.
Lee JH; Basith S; Cui M; Kim B; Choi S
SAR QSAR Environ Res; 2017 Oct; 28(10):863-874. PubMed ID: 29183231
[TBL] [Abstract][Full Text] [Related]
17. Assessment of CYP2C9 Structural Models for Site of Metabolism Prediction.
Zhang X; Xu M; Wu Z; Liu G; Tang Y; Li W
ChemMedChem; 2021 Jun; 16(11):1754-1763. PubMed ID: 33600055
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase.
Hosaka S; Murayama N; Satsukawa M; Uehara S; Shimizu M; Iwasaki K; Iwano S; Uno Y; Yamazaki H
Drug Metab Dispos; 2015 Jul; 43(7):1119-22. PubMed ID: 25948712
[TBL] [Abstract][Full Text] [Related]
19. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
20. Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT).
Sodhi JK; Halladay JS
Methods Mol Biol; 2021; 2342():765-779. PubMed ID: 34272716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
